Substantial evidence from epidemiological studies suggests that caffeine may be protective against the cognitive decline seen in dementia and Alzheimer's disease (AD). This evidence was reappraised by the authors of the original studies in this special issue of the Journal of Alzheimer's Disease [1,2], and, despite methodological differences between the studies, the data was confirmed by the valuable meta-analysis of Santos and colleagues [3]. Notably, epidemiological studies corroborated by meta-analysis [4] also suggest that caffeine may be protective against Parkinson's disease [5].An inverse relationship between caffeine consumption and neurodegenerative disorders thus appears compelling based on these epidemiological studies. However, epidemiological studies have significant limitations. Even though the studies mentioned above were controlled for many confounding factors, unknown factors may have influenced the experimental results. In this regard, the study by Lawrence Whalley's group [6] is particularly interesting. They used a Scottish dataset to examine the mental ability of the participants when they were children and compared it to their present caffeine intake. Since mental abilities in the young may be strong predictors of the development of AD at an old age [7], it could be that brighter children, presumably carrying a lower risk, would consume more caffeine during their lifetime to meet high intellectual and occupational demands, thus driving the association between caffeine and cognitive decline. The present study clearly rules out this hypothesis, and, in fact, those subjects with higher childhood mental ability, who would lat-